GlassScriptPhysician profile
Rosemary Lethbridge
NPI 1508166935
$4,745.57
in general payments reported to CMS, 2019-2025
32 companies · $1,019 in 2025
The $1,019 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $639 · 2022: $756 · 2023: $1,207 · 2024: $1,126 · 2025: $1,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,350.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,019.87 | 2021-2025 | |
| Novo Nordisk INC | $671.76 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $510.46 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $497.41 | 2021-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Lilly USA, LLC | $257.05 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $216.08 | 2021-2022 | |
| Pfizer INC. | $189.24 | 2023-2025 | |
| Amgen INC. | $183.08 | 2021-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.84 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $125.83 | 2024 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.52 | 2023-2024 | Caplyta |
| Exact Sciences Corporation | $93.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Baxter Healthcare | $86.42 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Mylan Specialty L.P. | $73.62 | 2023-2024 | Yupelri |
| Astellas Pharma US INC | $58.26 | 2024-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56.03 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $50.72 | 2023 | |
| Gilead Sciences, INC. | $42.76 | 2021 | |
| Philips North America LLC | $41.01 | 2024 | (Ck6) Holter |
| Boston Scientific Corporation | $38.94 | 2024 | |
| Merck Sharp & Dohme LLC | $31.20 | 2021 | |
| Alexion Pharmaceuticals, INC. | $30.56 | 2023 | |
| Vanda Pharmaceuticals INC. | $27.61 | 2022 | |
| Kyowa Kirin, INC. | $27.51 | 2025 | |
| Dexcom, INC. | $24.58 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.20 | 2023 | Tradjenta |
| Otsuka America Pharmaceutical, INC. | $23.62 | 2023 | Nuedexta |
| Sanofi-Aventis U.S. LLC | $22.53 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.38 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2024 | Trintellix |
| Amarin Pharma, INC. | $14.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosemary Lethbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.